266 related articles for article (PubMed ID: 19108693)
1. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
Harro CD; Robertson MN; Lally MA; O'Neill LD; Edupuganti S; Goepfert PA; Mulligan MJ; Priddy FH; Dubey SA; Kierstead LS; Sun X; Casimiro DR; DiNubile MJ; Shiver JW; Leavitt RY; Mehrotra DV;
AIDS Res Hum Retroviruses; 2009 Jan; 25(1):103-14. PubMed ID: 19108693
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH; Brown D; Kublin J; Monahan K; Wright DP; Lalezari J; Santiago S; Marmor M; Lally M; Novak RM; Brown SJ; Kulkarni P; Dubey SA; Kierstead LS; Casimiro DR; Mogg R; DiNubile MJ; Shiver JW; Leavitt RY; Robertson MN; Mehrotra DV; Quirk E;
Clin Infect Dis; 2008 Jun; 46(11):1769-81. PubMed ID: 18433307
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
5. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.
Asmuth DM; Brown EL; DiNubile MJ; Sun X; del Rio C; Harro C; Keefer MC; Kublin JG; Dubey SA; Kierstead LS; Casimiro DR; Shiver JW; Robertson MN; Quirk EK; Mehrotra DV
J Infect Dis; 2010 Jan; 201(1):132-41. PubMed ID: 19929694
[TBL] [Abstract][Full Text] [Related]
6. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).
Baden LR; Walsh SR; Seaman MS; Johnson JA; Tucker RP; Kleinjan JA; Gothing JA; Engelson BA; Carey BR; Oza A; Bajimaya S; Peter L; Bleckwehl C; Abbink P; Pau MG; Weijtens M; Kunchai M; Swann EM; Wolff M; Dolin R; Barouch DH
J Infect Dis; 2014 Oct; 210(7):1052-61. PubMed ID: 24719474
[TBL] [Abstract][Full Text] [Related]
7. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
8. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
11. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
[TBL] [Abstract][Full Text] [Related]
13. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
[TBL] [Abstract][Full Text] [Related]
15. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
[TBL] [Abstract][Full Text] [Related]
16. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.
Nicholson O; DiCandilo F; Kublin J; Sun X; Quirk E; Miller M; Gray G; Pape J; Robertson MN; Mehrotra DV; Self S; Turner K; Sanchez J; Pitisuttithum P; Duerr A; Dubey S; Kierstead L; Casimiro D; Hammer For The Merck V/Hiv Vaccine Trials Network Study Team SM
AIDS Res Hum Retroviruses; 2011 May; 27(5):557-567. PubMed ID: 20854108
[TBL] [Abstract][Full Text] [Related]
18. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
20. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
